AKT1 and endometrial cancer: MiR‐423 high expression induces the sensitivity of endometrial cancer cells to cisplatin by causing loss of PTEN and activation of AKT. Therefore, miR‐423 is implicated as a predictive biomarker of cisplatin chemotherapy response in endometrial cancer.45